Evaluation of Safety Profile in a Cohort Study of Inhaled TQC3721 Suspension in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Latest Information Update: 17 Mar 2026
At a glance
- Drugs TQC 3721 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions; Registrational
- Sponsors Chia Tai Tianqing Pharmaceutical Group
Most Recent Events
- 17 Mar 2026 New trial record